









Markets
/
Stocks
/
nasdaq-cue
/

Cue Biopharma Inc

CUE

0.320USD

+0.004+1.27%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

24.90MMarket Cap

LossP/E TTM



Cue Biopharma Inc

0.320

+0.004+1.27%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cue Biopharma Inc

Currency: USD Updated: 2026-02-06

Key Insights

Cue Biopharma Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 154 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 5.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cue Biopharma Inc's Score

Industry at a Glance

Industry Ranking

154 / 392

Overall Ranking

299 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Cue Biopharma Inc Highlights

StrengthsRisks

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 645.81% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.29M.

Overvalued

The company’s latest PE is -0.77, at a high 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 227.06K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.71.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

5.000

Target Price

+1481.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cue Biopharma Inc is 6.05, ranking 295 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 2.15M, representing a year-over-year decrease of 35.58%, while its net profit experienced a year-over-year decrease of 14.00%.

Score

Industry at a Glance

Previous score

6.05

Change



Financials

6.37

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.89

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.10

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cue Biopharma Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cue Biopharma Inc is 7.34, ranking 133 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.77, which is -39.56% below the recent high of -0.47 and -379.13% above the recent low of -3.70.

Score

Industry at a Glance

Previous score

7.34

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 154/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Cue Biopharma Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 6.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

5.000

Target Price

+1481.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Cue Biopharma Inc

CUE

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cue Biopharma Inc is 5.36, ranking 319 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.43 and the support level at 0.24, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.34

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.001

Neutral

RSI(14)

43.019

Neutral

STOCH(KDJ)(9,3,3)

24.718

Neutral

ATR(14)

0.041

High Vlolatility

CCI(14)

-75.892

Neutral

Williams %R

79.160

Sell

TRIX(12,20)

-0.341

Sell

StochRSI(14)

50.707

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.323

Sell

MA10

0.344

Sell

MA20

0.342

Sell

MA50

0.394

Sell

MA100

0.557

Sell

MA200

0.655

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cue Biopharma Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 28.38%, representing a quarter-over-quarter decrease of 4.39%. The largest institutional shareholder is The Vanguard, holding a total of 3.01M shares, representing 3.83% of shares outstanding, with 2.18% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Bleichroeder LP

6.82M

Catalytic Wealth RIA, LLC

3.43M

+3.00%

The Vanguard Group, Inc.

Star Investors

3.04M

-4.64%

Geode Capital Management, L.L.C.

800.77K

+15.69%

Boothbay Fund Management, LLC

610.96K

Robertson Stephens Wealth Management, LLC

478.50K

BlackRock Institutional Trust Company, N.A.

446.59K

BofA Global Research (US)

324.52K

-0.02%

Sarraf (Pasha)

323.86K

Advisory Research, Inc.

257.23K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cue Biopharma Inc is 1.49, ranking 310 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.50. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.